Cytokine-induced killer (CIK) cells: from basic research to clinical translation.
Cytokine-induced killer (CIK) cells: from basic research to clinical translation.
复制标题
细胞因子诱导的杀伤（CIK）细胞：从基础研究到临床转化。
DOI：
10.1186/s40880-015-0002-1
复制
发表时间：
2015-03-05
影响因子：
--
通讯作者：
Han W
中科院分区：
文献类型：
--
作者：
Guo Y;Han W
大量的基础研究和临床研究证实了CIK细胞治疗恶性肿瘤的安全性和可行性。本文就近年来有关CIK细胞生物学特性及临床应用的文献进行综述。在癌症的进展阶段，已经实施了许多CIK细胞的临床试验，为未来提供了CIK细胞的潜在广泛应用。本文还对CIK细胞与其他过继免疫细胞的临床应用作了简要比较。然而，目前CIK细胞的制备还没有统一的标准或规模化。由于使用了自体CIK细胞，因此难以评价总体临床反应。在此基础上，对CIK细胞制备的统一标准和通用来源以及CIK细胞联合化疗或单独化疗作为主要策略提出了几点建议。CIK细胞免疫治疗的大规模、对照、分组、多中心临床试验应在严格的监管下进行。这些干预措施可能有助于改善未来的临床应用，并提高CIK细胞对广泛的恶性肿瘤的临床疗效。
The accumulation of basic researches and clinical studies related to cytokine-induced killer (CIK) cells has confirmed their safety and feasibility in treating malignant diseases. This review summarizes the available published literature related to the biological characteristics and clinical applications of CIK cells in recent years. A number of clinical trials with CIK cells have been implemented during the progressive phases of cancer, presenting potential widespread applications of CIK cells for the future. Furthermore, this review briefly compares clinical applications of CIK cells with those of other adoptive immunotherapeutic cells. However, at present, there are no uniform criteria or large-scale preparations of CIK cells. The overall clinical response is difficult to evaluate because of the use of autologous CIK cells. Based on these observations, several suggestions regarding uniform criteria and universal sources for CIK cell preparations and the use of CIK cells either combined with chemotherapy or alone as a primary strategy are briefly proposed in this review. Large-scale, controlled, grouped, and multi-center clinical trials on CIK cell-based immunotherapy should be conducted under strict supervision. These interventions might help to improve future clinical applications and increase the clinical curative effects of CIK cells for a broad range of malignancies in the future.